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The trend of disruption
in the functional brain network
topology of Alzheimer’s disease
Alireza Fathian1, Yousef Jamali1,2*, Mohammad Reza Raoufy3 & for the Alzheimer’s Disease
Neuroimaging Initiative*
Alzheimer’s disease (AD) is a progressive disorder associated with cognitive dysfunction that alters the
brain’s functional connectivity. Assessing these alterations has become a topic of increasing interest.
However, a few studies have examined different stages of AD from a complex network perspective
that cover different topological scales. This study used resting state fMRI data to analyze the trend of
functional connectivity alterations from a cognitively normal (CN) state through early and late mild
cognitive impairment (EMCI and LMCI) and to Alzheimer’s disease. The analyses had been done at the
local (hubs and activated links and areas), meso (clustering, assortativity, and rich-club), and global
(small-world, small-worldness, and efficiency) topological scales. The results showed that the trends of
changes in the topological architecture of the functional brain network were not entirely proportional
to the AD progression. There were network characteristics that have changed non-linearly regarding
the disease progression, especially at the earliest stage of the disease, i.e., EMCI. Further, it has been
indicated that the diseased groups engaged somatomotor, frontoparietal, and default mode modules
compared to the CN group. The diseased groups also shifted the functional network towards more
random architecture. In the end, the methods introduced in this paper enable us to gain an extensive
understanding of the pathological changes of the AD process.
Alzheimer’s disease is an irreversible and progressive brain disorder that is the fifth cause of death worldwide
and does not have a pharmacological treatment for cure or p
 revention1,2. AD progression can be considered as
a continuum from CN through EMCI and LMCI, and to AD, characterized by the loss of memory and cognitive
dysfunction. In more detail, it has been shown that the transition probabilities from MCI to more severe states of
AD at age 65 is 14% higher than the transition from CN, and this likelihood is increasing by a ge3. Moreover, the
studies show that these disorders are associated with dysfunction in the whole brain neural connectivity rather
than a local brain region4–6. Therefore, a non-invasive and computational method for modeling the connectivity
across the whole brain can help to understand the alterations in the brain network architecture corresponding to
the disease progression and provide an opportunity for early diagnosis and understanding of the disease process.
In this regard, the use of graph-theoretical methods and complex network theory for modeling the brain as an
interconnected network of brain regions have been a focus of interest in recent y ears7,8. In most of the studies,
the general framework for developing the brain networks include the selection of spatial and temporal scale
and resolution of the study d
 ata9–13, the appropriate atlases that divide the brain into distinct r egions14, the type
of connection among regions (anatomical, functional, or effective connectivity)15,16, and finally the methods of
estimating these c onnectivities17–19.
Resting-state functional magnetic resonance imaging (rs-fMRI), which measures the neural activity in the
resting state based on the blood-oxygen-level-dependent (BOLD) contrast, has been widely used to estimate
the functional connectivity network of the b
 rain20,21. Studies indicate the emergence of several complex network phenomena such as a ssortativity22,23, rich-club24,25, clustering26,27, and small-world28,29 in these networks.
The modularity and the importance of hub regions have also been discussed in several studies30–32. Further,
considering the sensitivity of these networks to brain d
 isorders33–35, many studies have aimed to develop computational methods for diagnosing and understanding of the disease process36–38. Specifically, in the case of AD
and its early stages, many studies reported the disturbance of the functional network architecture, indicating the
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Figure 1.  The similarity between study groups follows a trend proportional to the trend of disease progression.
(a) The Jaccard similarity coefficient between the four main group networks. (b) For each study group, the
23 subjects of each group were randomly divided into two subgroups of 11 and 12 networks. Then, the mean
networks of these 12 and 11 subjects were constructed, and the Jaccard similarity coefficient between these
two mean networks was computed. This process was repeated 100 times resulting in 100 Jaccard similarity
coefficient matrices. This panel shows the element-wise mean and SD of these matrices.
disappearance of c lustering39 and rich-club40 phenomena, alterations to the small-world p
 henomena41,42, decrease
in the functional connectivity link weights43,44, and the changes in the spatial distribution of the hub regions
(high ranked regions) towards the frontal areas of the brain43,45–47. However, to the best of our knowledge, none
of the studies have done a comprehensive comparative assessment of the functional brain network of patients
with AD and its early stages that include all of those subjects mentioned above.
The human brain has an intrinsic multi-scale architecture48, which is emerged in different aspects of the data:
spatial, temporal, and topological aspects13. In this study, the alterations in the human brain functional connectivity network corresponded to the progression of the disease from CN through EMCI and LMCI, and to AD
were assessed using multi-scale topological analysis. For each study group, a functional connectivity network
of 360 brain regions was computed. The results of different analyses that have been done on these networks are
divided into three topological scales: analyses at the scale of the whole network (global), analyses at the single
vertex scale (local), and analyses that are in between local and global scales (mesoscale)13.
The core question throughout this paper is whether these alterations are following a trend proportional to
the disease progression in the continuum from CN to AD. The presence of such trends is perceptible in most
of the results in this study. However, in some of them, the trends are not entirely proportional to the disease
progression and behave differently in the early stages of the AD spectrum. Further, the analysis showed that the
functional brain network tends to shift toward a more randomized architecture by the disease progression. Also,
it has been observed that the frontoparietal, somatomotor, and default mode modules are affected more than
other modules introduced in the next section.

Results

The results of this study are mainly obtained from the comparative analysis of 4 group networks, each representing a study group’s functional connectivity network. In order to construct these networks, the fMRI and
T1-weighted (T1w) images of 92 subjects (23 subjects for each study group) were passed through a processing
pipeline that includes the preprocessing using fMRIPrep 20.0.0 (49,50, RRID:SCR_016216), extracting 36 nuisance
regressors, parcellating the brain surface area into 360 regions, constructing connectivity network among these
regions with Pearson correlation coefficient (PCC), computing the mean of the networks that belong to subjects
within each study group, and finally, thresholding these four mean networks. The overall processing pipeline can
be found in Supplementary Fig. S1. We used an alpha level of .05 for all statistical tests presented in this study.

Global network analysis. Significant differences were revealed at the global level analysis. The Jaccard

similarity coefficient is a measure for evaluating the correlation and the similarity among two vectors. This
measure which is between 0 and 1, quantifies the similarity among each pair of vectors so that the higher outputs
indicate the higher similarity among the elements of these vectors. Computing this measure among vectorized
adjacency matrices (a matrix that use to represent a network, where the value of the element (i, j) of this matrix
equals the weight of the link between the vertices i and j.) corresponded to the 4 group networks were showed
that the similarity between the CN network and disease networks were decreased by the progression of the disease (Fig. 1a). However, the existence of similarity between the brain networks of the subjects belonging to the
same study group was still unclear. To obtain a more reliable comparison that takes into account these similarities, the samples of each study group were randomly divided into two subgroups of 12 and 11 samples. Similar
to the process explained in the “Methods and materials” section for computing the mean network of each study
group based on its 23 samples, two different mean networks were generated for each study group based on these
two subgroups of samples. Then, the Jaccard similarity coefficient among the 11-samples mean networks and
the 12-samples mean networks were computed. This process was repeated 100 times, resulting in 100 similarity
matrices . Then, the element-wise mean and standard deviation (SD) over these matrices were computed, and
the results showed the existence of almost similar trends (Fig. 1b). Further, this similarity has also been evaluated based on the PCC method and resulted in almost similar trends, which are shown in Supplementary Fig. S2
online.
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Study group

CN

EMCI

LMCI

AD

p

F

The average strength of the links
Total strength

9.35 ± 5.4

7.84 ± 4.9

7.77 ± 4.5

7.56 ± 3.8

< 0.001

8.76

Long links

0.0068 ± 0.0494

0.0050 ± 0.0443

0.0031 ± 0.0339

0.0029 ± 0.0323

< 0.001

60.76

Short links

0.0500 ± 0.1360

0.0519 ± 0.1488

0.0539 ± 0.1477

0.0541 ± 0.1506

< 0.001

46.19

Inter-module links

0.0022 ± 0.1031

0.0059 ± 0.0876

0.0092 ± 0.0861

0.0108 ± 0.1018

< 0.001

146.3

Intra-module links

0.1695 ± 0.1478

0.1493 ± 0.1274

0.1309 ± 0.1178

0.1218 ± 0.1314

< 0.001

28.13

Pairwise comparison

CN-AD

EMCI-AD

LMCI-AD

CN-EMCI

CN-LMCI

EMCI-LMCI

The pairwise t-test comparison
Total strength

< 0.001

0.287

0.002

0.001

0.234

0.038

Long links

< 0.001

< 0.001

0.001

0.061

< 0.001

< 0.001

Short links

< 0.001

0.911

< 0.001

< 0.001

< 0.001

< 0.001

Inter-module links

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

0.054

Intra-module links

0.190

< 0.001

0.200

< 0.001

0.010

< 0.001

Table 1.  General information about the distribution of the links of the study networks. The top table shows
the average strength of the links, which are grouped into long or short links and inter-module or intra-module
links. The significance of the pairwise differences is assessed using the t-test and is shown in the bottom table.

The mean and SD of vertex strength (the total weight of the vertex connections) also had a decreasing trend.
Furthermore, the links were classified into short and long links based on their euclidean length (the short (long)
links were defined as the links that the euclidean distance between its vertices is smaller (larger) than the average
distance among all vertices.). For each group network, the average weight of the long links and the average weight
of the short links was computed. As shown in Table 1, there was a decreasing trend of the long link weights and
an increasing trend of the short link weights proportional to the progression of the disease. In general, there was
a significant difference among nodal values of group networks shown in Table 1 (p < 0.001), indicating that the
total strength and the strength of the long links and the intra-module links are decreasing while the strength of
the short links, and the inter-module links are increasing by the disease progression.
There was also an inverse relationship between the local and global efficiency, which are measures for the
efficiency of information exchange over the networks. The global efficiency measures the information exchange
over the whole network, whereas the local efficiency measures the fault-tolerant of the network by quantifying
the information exchange between the neighbors of each vertex when that vertex is removed51. While local
efficiency in the CN group was higher than in other groups, global efficiency in the CN group was lower than
LMCI and AD groups (Fig. 2d).
The small-world (six degrees of separation) phenomenon describes that it is possible to reach any network
vertex from other vertices by passing through a small chain of connected vertices. It has been shown that in
small-world networks, the average shortest path length (< l >) grows logarithmically with the network size. This
phenomenon can be evaluated by measuring < l > and the growth rate of the average number of vertices within a
distance less than or equal to l from any given vertex (M(l)). It has been shown that in small-world networks, M(l)
is increasing faster than the exponential growth52. The M(l) function plotted in Fig. 2a and the values of < l >,
shown in Fig. 2b, both suggest that the group networks have the small-world property. However, these figures
indicate that, similar to the global efficiency shown in Fig. 2d; the changing patterns are not quite proportional to
the disease progression. Specifically, in almost all of the figures mentioned above, the only study group which is
not following the expected trend is the EMCI group. The existence of the small-world phenomenon along with the
high value of average clustering coefficient (< C >), will lead to a more specific emergence property of complex
networks called small-worldness. σ which is equals to the division of the normalized < l > by the normalized
< C >, is a measure of evaluating this new phenomenon explained in the section “Methods and materials”. Figure 2d indicates that in all networks, σ > 1, which means that they all have the small-worldness property. This
figure also indicates that σ , and consequently the small-worldness, increase by the disease progression with the
exception of the EMCI group, which is not following the trend. There was also a significant difference between the
nodal clustering coefficient (p < 0.001) and the shortest path length (p < 0.001) of the group networks, indicating
that the networks tend to become less clustered and more small-world by the disease progression.

Mesoscale network analysis. The analysis that had been done in the mesoscale indicates the existence of
trends similar to the analyses at the global scale.
Clustering, assortativity, and rich‑club. The clustering, assortativity, and rich-club phenomena have been used
to describe the higher-level architecture of a complex network. The high value of < C > indicates the presence
of highly interconnected groups of vertices within the network. This measure which is depicted in the second
bar plot of Fig. 2d, shows that the clustering phenomenon is decreasing with the disease progression. The assortativity phenomenon is characterized when neighbor vertices are likely to have similar degrees. In Fig. 2b, the
increasing diagram of the average degree of the nearest neighbors for vertices of degree k (knn (k)) indicates the
presence of this phenomenon. This figure and the last bar plot in Fig. 2d showing the PCC between the degrees
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Figure 2.  The emergence of the small-worldness, assortativity, and rich-club phenomenon in the group
networks. (a) M(l) plot showing the average number of vertices within a distance less than or equal to l from
any given vertex is almost increased by the disease progression and suggests that the group networks have
the small-world property that is almost stronger in the disease networks. Two graphs on the right-hand side
are toy examples to provide intuition on the relationship between the small-world property and randomness,
demonstrating the increase in the randomness of network connections (from bottom to top), which leads to
the increase in the emergence of the small-world property. The bottom network is more regular, whereas the
top one is more random. As a result, the average shortest path length is shorter in the random network (top)
than the regular one (bottom), causing the regular network to be less small-world. (b) Knn (k) plot showing the
average degree of the nearest neighbors, for vertices of degree k, is almost decreased by the disease progression
and suggests that the group networks have assortative architecture, and this assortative matching follows a
decreasing trend proportional to the disease progression. Two graphs on the right-hand side are toy examples
of assortative (top) and disassortative (bottom) networks to provide intuition on the assortative patterns.
As it is obvious, in the bottom network, high degree vertices are more connected with low degree vertices
(disassortative pattern), whereas, in the top network, its vertices tend to make connections with other vertices
that have similar degrees (assortative pattern). (c) ρ(k) plot showing the amount of inter-connectivity among
vertices of degree higher than k is almost decreased by the disease progression and suggests that the rich-club
phenomenon is disappearing by the disease progression. Two graphs on the right-hand side are toy examples
of networks with (top) and without (bottom) rich-club. In the bottom network, there is no significant interconnectivity among high-degree vertices (rich vertices). However, in the top network, which is an example of
a rich-club network, high-degree vertices are completely inter-connected. (d) The bar plots showing < C >,
< l >, global efficiency, local efficiency, σ (normalized < C >/ normalized < l >), and r (PCC between the
degrees of all vertices at either ends of a link).
of all vertices at either ends of a link (r) in each group network, also indicate that the assortativity is disappearing by the disease progression. The rich-club phenomenon is characterized when large degree vertices are more
interconnected with each other than with the smaller degree vertices. The diagram in Fig. 2c plotting the fraction
of links connecting vertices with degree higher than k out of the maximum number of links that these vertices
can possibly share (ρ(k)), indicates the presence of the rich-club phenomenon, which is disappearing by the
disease progression.
Modular analysis. The 360 brain regions were classified into seven modules based on a well-known parcellation
provided by Yeo et al.53 (Fig. 3a). Then, the topological architecture of intra-module and inter-module connection networks was analyzed. First, by reorganizing the position of vertices in each group network’s adjacency
matrix based on this classification, a substantial structure that was disappearing with the progression of the
disease was observed (see Supplementary Fig. S3 online). Then, the average weight of the intra-module links and
the average weight of the inter-module links were computed for each group network. As it is shown in Table 1,
there was an increasing trend of the inter-module link weights and an increasing trend of the intra-module link
weights proportional to the progression of the disease, and there was a significant difference among nodal values
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Figure 3.  The overall gradually changing patterns of highly-weighted links are following a trend proportional to
the disease progression. (a) The spatial distribution of the 7-module parcellation. (b) The top 1 percent highlyweighted links of each group network. Vertex color represents the module the vertex belongs to, and the vertex
size is proportional to the vertex strength. It shows that there is a trend towards the increase in the number of
default mode links as well as the decrease in the inter-hemisphere links in dorsal attention. Visualizations were
created using ggseg 1.6.1 R package54 (a) and Nilearn 0.6.2 (https://nilearn.github.io) (b).
of group networks (p < 0.001). Then, similar to the “Global network analysis” section where the PCC between
adjacency matrices of the group networks was measured, for each module, the PCC was computed among the
adjacency matrices of the modular sub-network of each group network. The results showed that these modules
are sensitive to the disease progression (see Supplementary Fig. S4 online).

Local network analysis. Several approaches have been attempted to attain a general conclusion about the

distribution of the regions and links that are most sensitive to the disease progression at the finest topological
scale.
In order to attain the most sensitive vertices, the spatial distribution of the hub vertices (vertices whose
strength is higher than mean + 2 × SD of all vertices) and the diseased-related activated and deactivated vertices
were calculated (Fig. 4b,c). Further, the frequency distribution of these vertices across the 7-module parcellation
introduced in the “Modular analysis” section is shown in Fig. 4a.
In order to attain the most sensitive links, for each disease stage two networks including the significantly
activated and deactivated links in the diseased network with respect to the CN network were constructed. As it
is obvious in Fig. 5a–d, These networks show a similar connectivity pattern among the seven modules, which
is becoming more and more apparent with disease progression. Further, we have statistically evaluated the significance of the patterns in the disease-related activated or deactivated networks, presented in Fig. 5. In order
to do that, we first categorized the links based on whether they were inter-module or intra-module. Then we
used the ANOVA test to check if there is a significant difference between the strength of the links belonging to
different inter-module (intra-module) categories. The results showed that these differences were significant with
p < 0.001 for all disease groups.
Also, the overall gradually changing pattern of the top 1 percent highly-weighted links of the group networks
is depicted in Fig. 3b. It shows a changing pattern toward increasing the number of default mode links and
decreasing the inter-hemisphere links in the dorsal attention module. Further, the significance of these trends
were statistically evaluated using the Chi-squared test with p < 0.001 for default mode links and p = .005 for
intra-hemisphere links in dorsal attention. In order to do that, we computed the number of inter-module (intramodule) links that appeared among the top 1 percent strongest links of each group network and also the number
of inter-module (intra-module) links that did not appear among them. Then we used the chi-squared test to see
whether these numbers were significantly different across study groups. We further categorized the links based on
both their module and the hemisphere they belong to and repeated the similar chi-squared test. In Supplementary
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Figure 4.  The distribution of hubs, activated areas, and deactivated areas shows that anterior regions are more
engaged in the diseased groups. (a) The frequency distribution across the 7-module parcellation. The left and
right sides of each sub-plot denoted by a vertical black line represent the distribution across modules limited
to the left and right hemispheres, respectively (b) The spatial distribution of the hub regions. The vertex size
is proportional to the vertex strength.

 (c) The spatial distribution of vertices that are activated (denoted by
) and deactivated (denoted by ) in the diseases. A vertex was called activated (deactivated) with respect to
disease if the subtraction of its strength in the disease network from the CN network was significantly larger
(smaller) than the similar value for other vertices. The vertex size is proportional to the value of this subtraction.
Visualizations in (b) and (c) were created using Nilearn package.

information, Fig. S5, we have provided detailed axial images indicating the brain areas in which the trends have
appeared. Also, a larger figure similar to Fig. 3b has been added to the Supplementary information (Fig. S6).
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Figure 5.  The alterations in the brain functional network induced by the disease progression. For each disease
stage, the connectogram of the links with significantly higher (activated) or lower (deactivated) weights
compared to the CN group is depicted in the top four panels: (a) connectogram of intra-module links activated
in each disease stage compared to the CN group, (b) Connectogram of inter-module links activated in each
disease stage compared to the CN group, (c) connectogram of intra-module links deactivated in each disease
stage compared to the CN group, and (d) Connectogram of inter-module links deactivated in each disease
stage compared to the CN group. For each disease group, the activated (deactivated) links compared to the CN
group are defined as the significantly larger (smaller) elements of the matrix resulting from the subtraction
of the disease network from the CN network. Diagrams are plotted based on the Hierarchical Edge Bundling
algorithm55 using ObservableHQ platform (https://observablehq.com). This algorithm allows bundling the intramodule links to get a more elegant presentation. Panel (e) indicates the activation or deactivation in the vertices’
strength by showing the top-view spatial distribution of the activated or deactivated vertices similar to Fig. 4c.
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Discussion

The main goal of this study was to investigate the alterations of the brain functional network topology in patients
with AD, LMCI, and EMCI compared to the CN patients from a multi-scale topological perspective. This study
attempted to find quantitative network measures that are proportional to the trend of brain deterioration from
CN patients through AD in order to suggest network-based biomarkers and also help to understand the disease
process. There are three general findings in this study. First, the functional brain network constructed in this
study is sensitive to the progression of AD. Second, the functional brain network of the diseased groups tends to
shift towards a more randomized and integrated architecture. Third, the present study suggests that the alterations in the network architecture may not be entirely proportional to the disease progression. In this regard,
the functional brain network architecture may go through a nonlinear process and behave differently in earlier
stages in the course of the disease progression.
Several study results suggested that the networks of the disease groups have larger global efficiency. These
results include the increase in the global efficiency, the small-world property, and the proportion of inter-module
to intra-module link weights. There are also several results suggesting the smaller local efficiency. These results
include the decrease in the local efficiency, < C >, and the proportion of intra-module to inter-module link
weights. This inverse relationship which is reported by previous brain s tudies56,57 can be explained by considering the increase of global efficiency as a compensatory mechanism for the decrease in the local efficiency. This
will leads to the efficiency in information spreading across the whole brain but the loss of efficacy in information
spreading in the finer scales of vertices and their neighbors. Considering the sparse nature of the brain networks,
the increase in the global and decrease in the local efficiency indicate that the disease networks have a more
random organization.
The analysis at the mesoscale revealed the alteration in the brain network organization in a way that causes
the disappearance of the assortative mixing and the rich-club phenomenon. ρ(k) is declining by the disease
progression, and in the case of the AD network, it is around 1 in almost everywhere, which means that the
brain network tends to behave more similarly to random networks. This significant rich-club reorganization
magnifies the importance of analyzing the alterations of the hub regions. The diseased networks’ hubs are more
distributed over the modules, and it is consistent with the claim that the diseased networks are more randomized
and integrated. Furthermore, the diseased groups have significantly more hubs located in anterior regions as
compared to the CN group. In more detail, the analysis of activated and deactivated areas shows that the default
mode, frontoparietal, and somatomotor modules have been significantly affected by the disease. As suggested
by Sha et al.58, this observation can find its explanation in the functionality of these modules: frontoparietal is
responsible for cognitive control, the default mode network is involved in internal emotional processing, selfreferential directed thought, and memory function58, and somatomotor is responsible for motor skill learning
and sensory perception. Furthermore, As it is also reported by other studies59,60, in addition to these modules, the
dorsal and ventral attention, which are respectively involved in the top-down and bottom-up attention process,
are also significantly involved in the networks of the disease-related alterations.
As described in the “Network efficiency” subsection, the quality of being random or regular in complex networks is closely related to global and local efficiency, small-worldness, average clustering, and average shortest
path length. Further, in the AD network, the disappearance of rich-club organization, the location hub regions
more uniformly distributed over the seven modules, and the decrease in the values of Fig. 1b indicates the
increase in the AD network randomness. In general, the present analysis results suggest that the brain network
tends to shift towards a random structure by the disease progression. There are also several measures for assessing
the integration in brain networks, including the decrease in average clustering and the intra-module link weights,
as well as the increase in average shortest path length and the inter-module link weights.
Despite several advantages in this study, some limitations should be addressed. First, due to the ill-posed
nature of constructing functional network problems and due to the lack of ground truth in any of the main
steps for generating functional networks out of neuroimaging data, many different strategies can be used for
this purpose61. Previous studies have shown that depend on the type of analysis, different strategies can lead to
different results14,62. Therefore, a comparative analysis of different strategies would help choose appropriate strategies depending on the different scales of topological network analysis and investigate whether a single strategy
would be appropriate for all scales. Second, Because of the same reasons mentioned in the first limitation, it can
be difficult to distinguish which strategy leads to the results that present a more valid biological interpretation61.
In the case of using these results for developing machine learning models, this lack of interpretability is acceptable, but interpreting these results in order to understand the disease process and the underlying mechanisms
that lead to the disease, should be done more carefully.
In conclusion, the analyses offered in this paper can help to gain an understanding of the topological changes
in the functional brain network architecture. Most previous studies for analyzing the AD spectrum, focused on
one topological scale. Using a multi-scale topological approach, this paper extensively demonstrated the pathological changes in the AD process. The issues mentioned in the limitations are the subjects of future works. A
comparative assessment of different functional networks constructed based on widely used strategies will help
to find strategies with higher sensitivity to the AD spectrum.

Methods and materials

Demographic and clinical information. Data used in the preparation of this article were obtained from
the ADNI database (adni.loni.usc.edu). Hundreds of patients took part in the ADNI project, which launched
in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal
of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography
(PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure
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Group

CN

EMCI

LMCI

AD

p

F

Demographic and clinical information
Number

23

23

23

23

-

-

Male, female

8,15

12,11

10,13

11,12

.673

-

Age (mean ± SD)

75.82 ± 9.44

75.29 ± 6.36

72.26 ± 7.05

77.75 ± 3.75

.396

1.00

MMSE (mean ± SD)

28.96 ± 1.17

28.32 ± 1.89

25.87 ± 3.86

20.32 ± 4.26

< 0.001

33.16

GDSCALE (mean ± SD)

1.04 ± 1.41

1.80 ± 1.85

1.94 ± 2.29

1.37 ± 1.32

.588

0.65

Global CDR (mean ± SD)

0.40 ± 0.13

0.39 ± 0.24

0.49 ± 0.25

0.96 ± 0.40

< 0.001

46.41

FAQ (mean ± SD)

0.25 ± 1.22

2.77 ± 4.22

5.06 ± 6.68

18.26 ± 7.87

< 0.001

46.61

NPI-Q (mean ± SD)

0.67 ± 1.54

2.47 ± 2.52

2.08 ± 1.98

4.85 ± 3.78

.002

5.41

Pairwise comparison

CN-AD

EMCI-AD

LMCI-AD

CN-EMCI

CN-LMCI

EMCI-LMCI

The pairwise t-test comparison
Age

0.932

0.539

0.202

0.878

0.512

0.919

MMSE

< 0.001

< 0.001

< 0.001

0.880

0.047

0.233

GDSCALE

0.817

0.961

0.982

0.523

0.596

0.999

Global CDR

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

0.515

FAQ

< 0.001

< 0.001

< 0.001

0.582

0.060

0.581

NPI-Q

0.429

0.633

< 0.001

0.987

0.067

0.029

Table 2.  Demographic and clinical information of the studied groups is shown in the top table. The pairwise
t-test comparisons of the clinical information are presented in the bottom table.

the progression of MCI and early AD. All statements were performed in accordance with relevant guidelines and
regulations. Table 2 shows the demographic and clinical information of the 92 study subjects, which are selected
from a sample of 96 subjects from the ADNI2 dataset. After estimating a correlation matrix for each participant,
in each disease group, a participant with less similarity among the group participants was excluded. The ANOVA
assessment showed that the study groups are aged-matched (F(3,88)=1.00149, p=0.396122.). Also, except for the
GDSCALE, other clinical information presented in Table 2, were significantly different across the study groups.
The information provided in Table 2 is obtained from different clinical and psychological tests. The MiniMental State Examination (MMSE) is a 30-point questionnaire that is the most common test for measuring
cognitive impairment used in clinical a ssessments63. The Geriatric Depression Scale (GDS) is a 30-item yes-or-no
questionnaire about the participants’ feelings over the past w
 eek64. The Global Clinical Dementia Rating (Global
CDR) is a rating scale for staging patients diagnosed with dementia65. The Functional Activities Questionnaire
(FAQ) measures instrumental activities of daily living, such as housework and shopping66. The Neuropsychiatric
Inventory Questionnaire (NPI-Q) measures the presence of Neuropsychiatric S ymptoms67.
Many studies have recently viewed the AD continuum as a continuous spectrum characterized by biomarkers
and neuropathological findings68–70. However, in the case of using functional brain network analysis for studying
the progression of AD, subdividing the continuum into distinct categories based on their clinical symptoms has
been widely used to represent the AD continuum71,72. It is worth mentioning that a growing number of studies
use biomarkers based on the levels of Amyloid-beta and p-tau proteins in cerebrospinal fluid73,74. The criteria
that ADNI2 used to classify Alzheimer’s disease continuum into four stages (CN, EMCI, LMCI, and AD), is
mainly based on MMSE score, Wechsler Memory Scale, and global CDR. More details on the inclusion/exclusion
criteria are available on the ADNI2 protocol document (adni.loni.usc.edu/wp-content/themes/freshnews-dev-v2/
documents/clinical/ADNI-2_Protocol.pdf). The fMRI and T1w images of 23 samples for each study group were
collected from the ADNI database of hundreds of patients. According to the ADNI data acquisition protocol,
Siemens (Slice Thickness = 4.0; TE = 13.0; TR = 3400.0) and Philips (Slice Thickness = 3.3; TE = 30.0; TR =
3000.0) scanners with Field Strength=3.0 were used for data acquisition. It is worth mentioning that, a growing
number of studies recently subdivided the MCI study cohort on the basis of AD-pathological load75,76. In this
study, the main reason for choosing the four stage categorization is the existence of many articles that use the
same categorization for analyzing AD via network s cience77–79, and it provides a better opportunity to compare
and validate our results with the other’s findings.

Preprocessing. The neuroimaging data was preprocessed using fMRIPrep 20.0.0, which is based on Nipype
1.4.2 (80,81, RRID:SCR_002502).
Anatomical data preprocessing. The T1w image was corrected for intensity non-uniformity (INU) with ‘N4BiasFieldCorrection’82, distributed with ANTs 2.2.083, RRID:SCR_004757], and used as T1w-reference throughout
the workflow. The T1w-reference was then skull-stripped with a Nipype implementation of the ‘antsBrainExtraction.sh’ workflow (from ANTs), using OASIS30ANTs as target template. Brain tissue segmentation of cerebrospinal fluid (CSF), white-matter (WM) and gray-matter (GM) was performed on the brain-extracted T1w
using ‘fast’ [FSL 5.0.9, RRID:SCR_00282384]. Brain surfaces were reconstructed using ‘recon-all’ [FreeSurfer
6.0.1, RRID:SCR_00184785], and the brain mask estimated previously was refined with a custom variation of
the method to reconcile ANTs-derived and FreeSurfer-derived segmentations of the cortical gray-matter of
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Mindboggle [RRID:SCR_00243886]. Volume-based spatial normalization to one standard space (MNI152NLin2009cAsym) was performed through nonlinear registration with ‘antsRegistration’ (ANTs 2.2.0), using brainextracted versions of both T1w reference and the T1w template. The following template was selected for spatial
normalization: ICBM 152 Nonlinear Asymmetrical template version 2009c87, RRID:SCR_008796; TemplateFlow
ID: MNI152NLin2009cAsym].
Functional data preprocessing. For each of the BOLD runs found per subject (across all tasks and sessions), the
following preprocessing was performed. First, a reference volume and its skull-stripped version were generated
using a custom methodology of fMRIPrep. Susceptibility distortion correction (SDC) was omitted. The BOLD
reference was then co-registered to the T1w reference using ‘bbregister’ (FreeSurfer) which implements boundary-based registration88. Co-registration was configured with six degrees of freedom. Head-motion parameters
with respect to the BOLD reference (transformation matrices, and six corresponding rotation and translation
parameters) are estimated before any spatiotemporal filtering using ‘mcflirt’ [FSL 5.0.989]. The BOLD time-series
were resampled onto the following surfaces (FreeSurfer reconstruction nomenclature): fsaverage5. The BOLD
time-series (including slice-timing correction when applied) were resampled onto their original, native space
by applying the transforms to correct for head-motion. These resampled BOLD time-series will be referred
to as preprocessed BOLD in original space, or just preprocessed BOLD. The BOLD time-series were resampled
into standard space, generating a preprocessed BOLD run in MNI152NLin2009cAsym space. First, a reference
volume and its skull-stripped version were generated using a custom methodology of fMRIPrep. Several confounding time-series were calculated based on the preprocessed BOLD: framewise displacement (FD), DVARS
and three region-wise global signals. FD and DVARS are calculated for each functional run, both using their
implementations in Nipype [following the definitions b
 y90]. The three global signals are extracted within the CSF,
the WM, and the whole-brain masks. Additionally, a set of physiological regressors were extracted to allow for
component-based noise correction [CompCor91]. Principal components are estimated after high-pass filtering
the preprocessed BOLD time-series (using a discrete cosine filter with 128s cut-off) for the two CompCor variants:
temporal (tCompCor) and anatomical (aCompCor). tCompCor components are then calculated from the top
5% variable voxels within a mask covering the subcortical regions. This subcortical mask is obtained by heavily
eroding the brain mask, which ensures it does not include cortical GM regions. For aCompCor, components are
calculated within the intersection of the aforementioned mask and the union of CSF and WM masks calculated
in T1w space, after their projection to the native space of each functional run (using the inverse BOLD-to-T1w
transformation). Components are also calculated separately within the WM and CSF masks. For each CompCor
decomposition, the k components with the largest singular values are retained, such that the retained components’ time series are sufficient to explain 50 percent of variance across the nuisance mask (CSF, WM, combined,
or temporal). The remaining components are dropped from consideration. The head-motion estimates calculated in the correction step were also placed within the corresponding confounds file. The confound time series
derived from head motion estimates and global signals were expanded with the inclusion of temporal derivatives
and quadratic terms for each92. Frames that exceeded a threshold of 0.5 mm FD or 1.5 standardised DVARS were
annotated as motion outliers. All resamplings can be performed with a single interpolation step by composing all
the pertinent transformations (i.e. head-motion transform matrices, susceptibility distortion correction when
available, and co-registrations to anatomical and output spaces). Gridded (volumetric) resamplings were performed using ‘antsApplyTransforms’ (ANTs), interpolation to minimize the smoothing effects of other kernels93.
Non-gridded (surface) resamplings were performed using ‘mri_vol2surf ’ (FreeSurfer).
Next, confound regression with 36-parameters (including 6 motion parameters of translation and rotation,
mean signal in white matter, mean signal in cerebrospinal fluid, and global signal, as well as their derivatives,
quadratic terms, and squares of derivatives) were conducted to the data resampled onto FreeSurfer fsaverage5
surface space92.

Network construction. The human connectome project’s multi-modal parcellation, version 1.0 (HCP_

MMP 1.0)94 were used to parcellate each participant’s data into 360 regions. It has been shown that this parcellation is more robust and sensitive to AD progression than many other widely used parcellations, and it is probably
the most detailed cortical in-vivo parcellation available to date14,95. The time series corresponding to each region
is then the mean of the time series of voxels within that region. Then, the weighted undirected functional connectivity network was obtained by computing the PCC between time series of all regions. In order to obtain a
single network for each study group, the mean network of each group was computed as the element-wise mean
of all networks belong to the subjects within that group. Finally, instead of using a constant threshold value to
remove weak links in each group, we used a data-driven method to compute a threshold value. This new criterion is inspired by the fact that complex networks have strong global efficiency as well as sparsity. Furthermore,
it has been shown that this approach has a good potential for the diagnosis of Alzheimer’s disease. For each
network, we searched for a thresholding value that maximizes the global efficiency (E) minus the proportion of
the strongest weights (PSW) (Eqs. 1, 2)96.

1
1  j∈N,j�=i ( dij )
E(t) =
(1)
n i∈N
n−1

PSW(t) =

Scientific Reports |
Vol:.(1234567890)

(2022) 12:14998 |


i∈W,i≥t i

j∈W j

https://doi.org/10.1038/s41598-022-18987-y

(2)

10

www.nature.com/scientificreports/
where N is the set of all vertices, n is the number of vertices, dij is the shortest path length between vertices i
and j, and W is the set of all weights. However, the results of this method were not very different from using the
same thresholds for each group, and the resulting thresholds were close to each other (CN: 0.093, EMCI: 0.086,
LMCI: 0.101, AD: 0.083).

Network analysis. The study of large-scale complex networks includes a wide range of statistical measures

that have been defined for the study of large-scale complex networks as characteristics for network architectures.
Most of these measures have specific real-world interpretations. However, some of them have been shown to be
more manifested in real-world networks, and more specifically the brain networks, representing their intrinsic
complexity97,98 (e.g., small-worldness and efficiency), heterogeneity99 (e.g., degree distribution, hubs), hierarchical structure24,100 (e.g., rich-club, assortativity, clustering, and hubs), integration (e.g., small-world, clustering,
local efficiency), and segregation (e.g., average shortest path length, global efficiency)32,101. This study used a
collection of most dominant measures that can evaluate these features and also capture different topological
scales13. Further, these measures have been widely used in studying the AD continuum40,47,102.
Network efficiency. The efficiency of information exchange throughout the networks can be assessed from local
and global perspectives51,103,104.
Having a small < l > leads to efficient information exchange from the global point of view. Accordingly,
several quantitative methods were introduced to assess this efficiency. The global efficiency, which is the inverse
sum of the shortest path length among vertices, is one of t hem51. The small-world property which is a common
emergence phenomenon among many real-world complex network systems, also guarantees high efficiency in
the information exchange from the global perspective. This measure that also calls the six degrees of separation,
exists if < l > scales slower than the logarithmic growth with the size of the network. M(l) is defined as the average number of vertices within a distance less than or equal to l from any given vertex. Then M(l) is expected to
grow faster than the exponential growth in the small-world n
 etworks52.
It has been shown that many real-world complex networks are mostly sparse networks with high < C >105
that will lead to the efficiency in the local information exchange. This efficiency can also be assessed by measuring the average efficiency of the sub-networks, including each vertex and its n
 eighbors51. Clearly, this efficiency
can not be attained if the network has a completely random organization. However, the sparse nature of these
networks, along with the existence of the small-world property, implies that these networks can not be like
regular networks, and there should be random rearrangements in the connections of these networks to form
hubs and connectivity backbones and leads to faster information exchange and decrease in < l >52. Therefore,
the emergence of both local and global efficiency, which can be explained by the trade-off between the regular
and random organization of the c onnections103, was recognized as a new phenomenon, called the small-worldness106. A straightforward approach for quantifying this phenomenon is to divide the normalized < l > by the
normalized < C > (σ =< l >rand /Crand ). The normalization can be done by dividing the actual value of each
measure by the value of the measure for a corresponding Erdős-Rényi random graph. A network is then said to
have small-worldness if σ > 1106.
Assortativity. The assortative property refers to the tendency of vertices to connect to other vertices with similar degree. In this study, this property was measured using two methods. First, the PCC between the degrees of
all vertices on either ends of a link was computed as:


je ke /E − [ e (je + ke )/(2E)]2
r =  2e

(3)
[ e (je + ke 2 )/(2E)] − [ e (je + ke )/(2E)2 ]
where je and ke denote the degree of the extremities of link e and E is the total number of links. This quantity lies
in the range −1 ≤ r ≤ 1, where −1 refers to disassortative networks and 1 refers to totally assortative n
 etworks107.
The second method measures the assortativity by computing the average degree of the nearest neighbors, for
vertices of degree k (knn (k)).
1 
knn (k) =
knn,i
(4)
Nk
i/ki =k

where Nk is the number of vertices with degree k and knn,i is the average degree of the nearest neighbors, for
the vertex i. If knn (k) is an increasing function of k, the average degree of the nearest neighbors, for vertices of
degree k will increases by k which means that the probability of these vertices being connected with large degree
vertices is increasing and this corresponds to an assortative m
 ixing107.
Rich‑club. The rich-club property indicates the tendency of high degree vertices, to be connected to each other
and forming clubs. It can be quantitatively measured as:

φ(k) =

2E>k
N>k (N>k − 1)

(5)

where E>k is the number of links among the vertices with degree larger than k, and N>k is the number of vertices with degree larger than k. In order to obtain a more representative measure, the φ(k) of the network under
study was normalized by dividing with the φ(k) of a random network with the same degree distribution as the
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network under study. This function is called ρran (k). If ρran (k) is an increasing function of k, the sub-networks
containing vertices with degree larger than k will be denser as k increases and this implies the presence of a
rich-club organization108.
Sensitive vertices and links. Given a scoring system for vertices, network hubs are defined as the vertices whose
score is significantly higher than others (> mean + 2 × SD ). In this study, we used strength as the scoring system. Additionally, by defining a new score as the subtraction of the score of the network under study (in here
the disease networks) from a reference network (in here the CN network), the activated regions in that network
with respect to the reference network, is then computed as the vertices that their new score is significantly higher
than others, respectively the deactivated regions are the ones that their new score is significantly lower. Further,
a scoring system for network links was defined by computing the difference between the adjacency matrix of the
disease networks and the CN network. Likewise, for each disease group, the activated (deactivated) links were
determined as links whose score is significantly higher (lower) than others.
Statistical analyses. In General, One-Way ANOVA and Chi-squared (χ 2) tests have been performed for continuous or categorical variables, respectively, throughout the results. Additionally, Kruskal-Wallis one-way analysis
of variance, which is a nonparametric alternative to the One-Way ANOVA test was used in this analysis (all with
p < 0.05).
Further, As it is also explained in the “Rich-club” and “Network efficiency” subsections, in order to assess the
significance of the rich-club and small-worldness, the φ(k) and the σ functions were included a standardization
part in which these functions were computed for a collection of 1000 randomly generated networks with the
same degree distribution as the original networks (based on edge_swap algorithm).
The main approach of this study was to perform complex network analysis on the brain connectivity in each
disease stage. Therefore, one goal was to estimate a single brain network for each stage of the disease. To do so,
as many other studies suggest109–112, averaging the networks over all participants within each group was the best
option for estimating the group networks. Indeed, one concern in this study was whether the group averaged
networks could represent the group participants. In this regard, a permutation test was designed that repetitively
creates two average networks for each disease group using random permutations and investigates whether these
average networks are more similar to each other than the average networks of other diseases (Fig. 1b).

Data availability

The four main group networks are available in Supplementary Materials, and all other intermediate data are
available from the corresponding author upon request. Further, the codes for this study are available at https://
github.com/Alirezafathian/fmriprediction.
Received: 19 April 2021; Accepted: 23 August 2022
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